Dear Authors,
If you believe that your paper was mistakenly rejected by other leading journals and you do not agree with final decision, the editors of Reports of Practical Oncology and Radiotherapy offer new fast track review. You may submit your manuscript to Reports of Practical Oncology and Radiotherapy together with all prior peer-reviews obtained from the other journal and your rebuttal letter. We guarantee review based decision within 72 hours from the time we will receive your manuscript.

Fast track submission process: Please submit the manuscript with all reviews and rebuttal letter by email to Dr. Michal Masternak ( for fast review processing. To assure immediate attention the email title must to include: RPOR-fast track- Last Name First Name (of corresponding author).

Volume 6, Number 1, 2001

The evaluation of clinical, histological and molecular predictive and grognostic factors in patients with advanced squamous cell cancer of the larynx, meso- and hypopharynx, floor of mouth irradiated after induction chemotherapy.

Małecki K.


Between 1988-1997 198 patients with HNSCC received induction chemotherapy. Clinical staging was as follows II-7(52%), III-45(20%), IV-146(64%). Patients received 1 to 4 cycles of Cisplatin + 5FU. Response to chemotherapy (CR or PR) was observed only in patients who received 2-4 cycles of chemotherapy. The best responses were observed in patients with laryngeal, mesopharyngeal and hypopharyngeal cancers, 55%. Radiotherapy was subsequently performed in 178(90%). Twenty patients were not irradiated because of poor performance status or progression of disease after chemotherapy. Radical radiotherapy was performed in 124 (5-year LC 38%, DFS 35%, DSS 43%, OS 30%). All 25 patients irradiated palliatively dyied during 26 months. The best results were observed in patients with laryngeal cancer; LC 48%, DFS 25%, DSS 32%, OS 22%. The most frequent failure was local recurrence in 29(23%) patients. In the next step of this study we want; 1) to assess prognostic and predictive value of selected clinical, histological and molecular factors by defining its influence on the chance of response to chemotherapy and chance of cure 2) to examine the correlation between theses factors and to establish if they give new predictive and prognostic information 3) to establish which of examined factors may be useful in selecting patients with advanced HNSCCs to combined modality treatment (chemotherapy + radiotherapy), and particularily in selecting patients with advanced laryngeal cancer to larynx preservation treatment. We will examine the cell cycle parameter Ki67, expression of p53 protein and expresion of (EGFr). There will be also reevaluated histological material (grading).

Signature: Rep Pract Oncol Radiother, 2001; 6(1) : 32-32

« back


Indexed in: EMBASE®, the Excerpta Medica database, the Elsevier BIOBASE (Current Awareness in Biological Sciences) and in the Index Copernicus.